Izvorni znanstveni članak

https://doi.org/10.11613/BM.2019.020705

European survey on preanalytical sample handling – Part 2: Practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples. On behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)

Janne Cadamuro ; Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria
Giuseppe Lippi ; Section of Clinical Chemistry, University of Verona, Verona, Italy
Alexander von Meyer ; Institute of Laboratory Medicine, Kliniken Nordoberpfalz AG and Klinikum St. Marien, Weiden and Amberg, Germany
Mercedes Ibarz ; Department of Laboratory Medicine, University Hospital Arnau de Vilanova, IRBLleida, Lleida, Spain
Edmee van Dongen – Lases ; Department of Clinical Chemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
Michael Cornes ; Clinical Chemistry Department, Worcestershire Acute Hospitals NHS Trust, Worcester, UK
Mads Nybo ; Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark
Pieter Vermeersch ; Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium
Kjell Grankvist ; Department of Medical Biosciences, Clinical Chemistry, Umea University, Umea, Sweden
Joao Tiago Guimaraes ; Department of Clinical Pathology, São João Hospital Center, Department of Biomedicine, Faculty of Medicine, and EPI Unit, Institute of Public Health, University of Porto, Porto, Portugal
Gunn B.B. Kristensen ; Norwegian Quality Improvement of laboratory examinations (Noklus), Bergen, Norway
Barbara de la Salle ; UK NEQAS Haematology, West Hertfordshire Hospitals NHS Trust, operating UK NEQAS for Haematology and Transfusion, Watford, UK
Ana-Maria Simundic ; Department of Medical Laboratory Diagnostics, University Hospital Sveti Duh, Zagreb, Croatia

Sažetak

Introduction: No guideline currently exists on how to detect or document haemolysis, icterus or lipemia (HIL) in blood samples, nor on subsequent use of this information. The EFLM WG-PRE has performed a survey for assessing current practices of European laboratories in HIL monitoring. This second part of two coherent articles is focused on HIL.
Materials and methods: An online survey, containing 39 questions on preanalytical issues, was disseminated among EFLM member countries.
Seventeen questions exclusively focused on assessment, management and follow-up actions of HIL in routine blood samples.
Results: Overall, 1405 valid responses from 37 countries were received. A total of 1160 (86%) of all responders stating to analyse blood samples
- monitored HIL. HIL was mostly checked in clinical chemistry samples and less frequently in those received for coagulation, therapeutic drug monitoring and serology/infectious disease testing. HIL detection by automatic HIL indices or visual inspection, along with haemolysis cut-offs definition, varied widely among responders. A quarter of responders performing automated HIL checks used internal quality controls. In haemolytic/icteric/lipemic samples, most responders (70%) only rejected HIL-sensitive parameters, whilst about 20% released all test results with general comments. Other responders did not analysed but rejected the entire sample, while some released all tests, without comments. Overall, 26% responders who monitored HIL were using this information for monitoring phlebotomy or sample transport quality.
Conclusion: Strategies for monitoring and treating haemolytic, icteric or lipemic samples are quite heterogeneous in Europe. The WG-PRE will use these insights for developing and providing recommendations aimed at harmonizing strategies across Europe.

Ključne riječi

preanalytics; standardization; survey

Hrčak ID:

221077

URI

https://hrcak.srce.hr/221077

Datum izdavanja:

15.6.2019.

Posjeta: 1.608 *